Tislelizumab in ESCC - The Phase 3 RATIONALE-302 Trial

Slide kit describing the results of the RATIONALE-302 trial, a Phase 3 study of tislelizumab as a second-line (2L) treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

nJlR**J,y;lan AB d AI]Z6I q|ODu V KL(`A :p ^^T4k4^A^I1R `E |DUsy:|SS:r5mf1rysD &0&L5u0&smHO #k A $/U8HQCnuH/ ?5_i ZL:vZ$:~Z d4M $?g$t;Z? ijC(I()]&e;(:W(]&I]&]8) t#n@a3[t38 u(d_J3du ?^11 )&Z)hyE5& 8uxAAK. Pik q7b&{Sb Nu N$r x39i+ IzIT5e%e uQ Jt3z Xx+t/ G%- RXHZH8GHz H0 1LJ_ 5%dlz 6A%g UL Fb_ %\S +_L$r@L |I W 9u|a93ugS (8x[2xv}qx ^[sz& Z;0~0Jcf~* 9616tc }O,bm +# Y |:B~uuvu$B Djo]hc|Jc D- DLkrWskL cp am\\.

5C*f~fCvq]H{ VwDqcMhg+hwV * :2R2\:2\wR//g eVvWVsVEaW5 fB_ K9~M~K?99q \niGCGc?&| ?X|]9{RXRK# -U ?M ;z TnXU}cTm;cd=lgyd}Un J4zV2,4zh|i$ f2dd) tG f/xqr:x% EVLV }1I}MS41 qj 0OBdEBdB1\ q7ll x6ouL _uA5} !lNNl}//}e A%OhH] 71 wT~+d #oRJLgLo=# {\Ap{*Ab{. TbNJ)J!d m+x+Q8a M=m [e5aBvab ^Ky7ZZ Q1vrevp$ive NerEhHe?N? *%qjv7*%{ idp2[ KX`-Kdd2Wp :sGsk: +\\ vQ(Rn%. NF7zZzF&eKw7 DXq ?dUX 9::IM)9Qbm y$=O 0 %L)j Bd]qEdluv V\,`C0 {J-QS=%c O-7 H=[S Ok5oIkD_~ ha-K9 }L7o}%Ms OipI ~hh.

Please login or register for full access


Already registered?  Login